Advertisement
Screener

Nektar Therapeutics (NKTR) Operating Leases, Rent Expense

1.9 / 5 stars · 30/81 Roast Me

Nektar Therapeutics Operating Leases, Rent Expense

Nektar Therapeutics (NKTR) reported Operating Leases, Rent Expense of $8.10 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.

Discontinued › Expense Statement › Operating Expenses

us-gaap:LeaseAndRentalExpense · last filed 2019-03-01

  • Nektar Therapeutics operating leases, rent expense for fiscal 2018 was $8.10M, a 72.34% increase from fiscal 2017.
  • Nektar Therapeutics operating leases, rent expense for fiscal 2017 was $4.70M, a 46.88% increase from fiscal 2016.
  • Nektar Therapeutics operating leases, rent expense for fiscal 2016 was $3.20M, a 0.00% change from fiscal 2015.
  • Nektar Therapeutics operating leases, rent expense for fiscal 2015 was $3.20M, a 0.00% change from fiscal 2014.
Period endOperating Leases, Rent Expense 12 month
2018-12-31$8.10M
10-K · filed 2019-03-01
2017-12-31$4.70M
10-K · filed 2019-03-01
2016-12-31$3.20M
10-K · filed 2019-03-01
2015-12-31$3.20M
10-K · filed 2018-03-01
2014-12-31$3.20M
10-K · filed 2017-03-01
2013-12-31$2.90M
10-K · filed 2016-02-29
2012-12-31$2.80M
10-K · filed 2015-02-26
2011-12-31$2.40M
10-K · filed 2014-02-27
2010-12-31$2.20M
10-K · filed 2013-03-01
2009-12-31$700.00K
10-K · filed 2012-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
UroGen Pharma Ltd. (URGN)$2.015B-18.42
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Generate Biomedicines, Inc. (GENB)United States$2.052B
Biohaven Ltd. (BHVN)United States$1.990B-3.83
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89